Certificate of Analysis

Report GSA-COA-000078-TESA10-20261030-8
Issued 2026-11-04 · Page 1 of 2

Scan to verify

Tesamorelin 10 mg


Order GSA-2026-000078 · 6A Labs · 3 vials of one product

Customer	6A Labs
Order	GSA-2026-000078
Label	Tesamorelin 10 mg
Vials tested	3 (A1, B1, C1)
Prepared	29 Oct 2026
Tested	30 Oct 2026, 02 Nov 2026
Tests	Identity, Purity, Content, Impurities, Conformity


IDENTITY
Tesamorelin
confirmed in all 3 vials

PURITY
99.4 %
mean of 3 vials (99.2-99.5 %)

HPLC chromatograms (UV, 214 nm), every vial



Mass spectrum of the main peak, vial A1 (17.09 min)



Results by vial

Vial	Identity	Purity (214 nm)
Vial A1	Confirmed	99.42 %
Vial B1	Confirmed	99.54 %
Vial C1	Confirmed	99.22 %
Average		**99.39 %**
Difference		**0.33 points**

Each tesamorelin vial was injected twice; its purity is the mean of the two injections. Difference = largest minus smallest vial. Purity is a share of the UV peak area.

APPROVED FOR RELEASE

Ian Ebert, Laboratory Director

Signed electronically
5 Nov 2026, 04:46 UTC
Release record: last page

Results are not covered by ISO/IEC 17025 accreditation.
Results relate only to the sample as received and tested.

Results

Identity	**Consistent with tesamorelin in every vial.** Measured mass 5135.8, 5135.8, 5135.8 (average 5135.8; expected 5135.9); retention time matching the tesamorelin reference standard (17.08 min).
Purity	**99.39 %** (mean of 3 vials; 99.22-99.54 %) by HPLC with UV detection at 214 nm.
Conformity between vials	**Not consistent.** Content of every vial within +/- 5 % of the three-vial mean: not met, largest difference 5.3 % (RSD 4.7 %). The same peptide is the main compound of every vial (tesamorelin); Purity of every vial within +/- 0.5 percentage points of the mean; Same impurity profile: no impurity of 0.3 % or more in one vial only: met. Criteria are the laboratory's batch-consistency limits for 3 vials; a formal content-uniformity test (USP <905>) needs 10 units.

Impurities

Every peak other than tesamorelin found in the vials, as a share of the UV peak area at 214 nm:

Peak (min)	Vial A1	Vial B1	Vial C1	Mean	What it is
1.50	0.20 %	0.26 %	0.23 %	0.23 %	An unidentified substance that is not a form of tesamorelin (its mass does not match).
12.62	0.17 %	-	-	0.06 %	An unidentified substance that is not a form of tesamorelin (its mass does not match).
13.46	-	-	0.14 %	0.05 %	A small unidentified peak (too small for its mass to be measured).
14.15	-	0.13 %	-	0.04 %	A small unidentified peak (too small for its mass to be measured).
15.88	-	-	0.13 %	0.04 %	An unidentified substance that is not a form of tesamorelin (its mass does not match).
21.02	0.15 %	-	-	0.05 %	An unidentified substance that is not a form of tesamorelin (its mass does not match).
22.11	-	-	0.28 %	0.09 %	A small unidentified peak (too small for its mass to be measured).


Trace peaks below 0.10 % add up to 0.05 % (vial A1), 0.06 % (vial B1), 0.00 % (vial C1). '-' = not found in that vial.

Net content

Vial	Net content	% of label
Vial A1	9.0 mg	90.0 %
Vial B1	8.2 mg	82.1 %
Vial C1	8.8 mg	87.8 %
Average	8.7 mg	86.6 %
Difference	0.79 mg (RSD 4.7 %)	7.9 points

Content is the mean of every injection of the vial's solution. Difference = largest minus smallest vial.

Zoomed views



Chain of custody

Receipt photograph of the vials: 29 Oct 2026 12:09, red cap (TESA 10 mg). Sample preparation was video-recorded on 29 Oct 2026 (4 recordings, each identified by its SHA-256 fingerprint): 1 tesa 10mg.mp4 (58 s, f8b72d2d6b6cf81834b7715fa95a48e622b92cdbbaa19dce12b4ce8762b2ee9e); 2 tesa 10mg.mp4 (35 s, 83ef15119df58fe51dffcd459cd51747492ac86d0833d57c86a4bdcba8f2f14d); 3 tesa 10mg.mp4 (46 s, 8673a2af79779d038a1d674c89e9c46b94e086a9417a53aa9c9c921688d4896a); 10mg tesa pt2.mp4 (130 s, 853a344b4da3851443292324daa8daf884c55b9bf6dba71a0e7fa2390526dfaf).

How it was tested

Liquid chromatography with UV and mass-spectrometry detection: Agilent 1290 Infinity II LC with a 6490 triple-quadrupole mass spectrometer. Column Polaris C18-A, 2.0 x 150 mm, 45 °C; water and acetonitrile, each with 0.1 % formic acid. Purity: UV peak area at 214 nm. Identity: molecular mass and retention time against a reference standard. Content: UV at 220 nm against a tesamorelin reference standard; the whole vial was dissolved. Each vial was made up to 1 mg/mL from its label claim in water.

Notes

Results apply only to the vials as received and tested. Purity is a share of the UV peak area, not a weight percentage. Identity is by molecular mass and retention time; the amino-acid sequence was not checked. The autosampler tray was warmer than its 4 °C set point during part of this test (up to 28 °C).

APPROVED FOR RELEASE

Signed electronically by a Gold Standard Analytics lab technician at release.
The signature is at the bottom of page 1; the release record, the last page of this certificate, gives the date and verification code.

Gold Standard Analytics

goldstandardanalytics.com

Release record

Report GSA-COA-000078-TESA10-20261030-8 · Certificate GSA-2026-650621

Customer and order	6A Labs · GSA-2026-000078
Sample and report	078-TESA10 · Tesamorelin 10 mg Certificate of Analysis
Report reference	GSA-COA-000078-TESA10-20261030-8
Certificate accession	GSA-2026-650621
Released and signed by	Ian Ebert, Laboratory Director
Date and time (UTC)	2026-11-05 04:46:16Z
Signature meaning	Approved for release. The signer reviewed this report and approved its release to its customer.
Approval reference	4686f198-3176-4032-ba57-ff19f4f59d33
Electronic signature	Signed electronically in a signed-in GSA staff account.
Original report SHA-256	367477d663608843e2e1ac9f258c15f080535b5ee9d24a741f91c64116bb44cd
Verify this certificate	https://goldstandardanalytics.com/coa/GSA-2026-650621

Scan to view this certificate online

Signature



Ian Ebert, Laboratory Director

Results are not covered by ISO/IEC 17025 accreditation. Development method; not validated.
Results relate only to the sample as received and tested.